5. Mental state: 1.4 Specific ‐ Average positive symptoms score (PANSS positive, negative MD favours NRI) ‐ short‐term (2‐12wks) ‐ Subgroup and sensitivity analysis.

Subgroup or sensitivity analysis (see text for details)	Number of trials	N	Mean difference	95% Confidence interval	I²
Overall outcome	5	294	‐0.16	‐0.96 to 0.63	0%
Reboxetine	4	279	‐0.24	‐1.05 to 0.57	0%
Clozapine‐only studies	2	221	‐0.15	‐1.02 to 0.72	0%
Excluding studies without clozapine; negative symptoms	3	256	‐0.22	‐1.04 to 0.60	0%
Fixed‐effect model	5	294	‐0.16	‐0.96 to 0.63	0%
Low risk of randomisation bias	2	58	‐0.76	‐2.93 to 1.40	0%